Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune SafiledCriticalNovimmune Sa
Priority to ARP060101076priorityCriticalpatent/AR052618A1/en
Publication of AR052618A1publicationCriticalpatent/AR052618A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
La presente se refiere a anticuerpos completamente humanos y fragmentos de los mismo, que se unen al interferon gamma humano (hIFNgamma), modulando así la interaccion entre IFNgamma y, su receptor, IFNgamma-R, y/o modular las actividades biologicas de IFNgamma. La presente además se refiere al uso de dichos anticuerpos anti-IFNgamma para la prevencion o tratamiento de trastornos relacionados con el sistema inmunologico y la mejora de un síntoma asociado con un trastorno relacionado con el sistema inmunologico.This refers to fully human antibodies and fragments thereof, which bind to human interferon gamma (hIFNgamma), thus modulating the interaction between IFNgamma and its receptor, IFNgamma-R, and / or modulating the biological activities of IFNgamma. The present further refers to the use of said anti-IFNgamma antibodies for the prevention or treatment of disorders related to the immune system and the improvement of a symptom associated with a disorder related to the immune system.
ARP0601010762006-03-202006-03-20
ANTIBODIES ANTI- INTERFERED GAMMA AND METHODS OF USING THEMSELVES
AR052618A1
(en)
COMPOUNDS DERIVED FROM DIHIDRO AND TETRAHIDRO OXAZOLOPIRIMIDINONAS REPLACED; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF CHICHOPHRENIA, EPILEPSY, BETWEEN OTHER DISEASES.
Methods and composition for the treatment of allergic diseases human stromal lymphopoietin receptor antibody (tslp) or antigen-binding portion thereof; polynucleotide that encodes it; host cell; pharmaceutical composition comprising it; and its use to treat an inflammatory disease or disorder in a subject
Compounds derived from substituted pyrazolo-quinazoline, modulators of the activity of protein kinases; pharmaceutical composition; and its use for the treatment of cancer, or a cell proliferative disorder.